TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Dr. Lal Path Labs Ltd.

LALPATHLAB on NSE · 19 Nov 2026

NIFTY 500

1,963.20 ▼ -0.11 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance

Filings

46 filings of LALPATHLAB since January 2025; the newest 40 below.

board outcome 16, dividend 8, presentation 8, transcript 8, credit rating 3, results 2

FiledTypeSubject
10 Nov 2026transcript
Acquisition, Dividend / buy-back, Guidance, Results
Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript
AI summary

Dr. Lal PathLabs filed the transcript of its Q2 & H1 FY27 earnings conference call held on November 04, 2026.

Management reported Q2 FY27 revenue of Rs. 874 crore, up 19.6%, and EBITDA of Rs. 280 crore (margin 32.1%); H1 FY27 revenue was Rs. 1,672 crore, up 19.4%.

Management said Q2 PAT was Rs. 194 crore, up 27.5%, and net cash as on 30 September 2026 stood at Rs. 1,746 crore.

The Board declared a second interim dividend of 50%, i.e. Rs. 5 per share.

On FY27 outlook, the CEO said revenue growth is currently looking to be in the high teens and EBITDA growth similar, with EBITDA slightly better than last year.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Nov 2026presentation
Results
Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation
AI summary

Dr. Lal PathLabs filed its Q2 & H1 FY27 earnings presentation for the quarter and half year ended September 30, 2026, approved by the Board on November 04, 2026.

Q2 FY27 revenue was Rs. 874 crore (up 19.6% from Rs. 731 crore), EBITDA Rs. 280 crore (up 25.1%, margin 32.1%) and PAT Rs. 194 crore (up 27.5%).

H1 FY27 revenue was Rs. 1,672 crore (up 19.4% from Rs. 1,400 crore), EBITDA Rs. 528 crore (up 26.7%) and PAT Rs. 364 crore (up 27.3%).

Q2 FY27 basic EPS was Rs. 11.5 versus Rs. 9.0 in Q2 FY26; H1 FY27 basic EPS was Rs. 21.7 versus Rs. 17.0.

The management commentary section of the presentation was listed in the table of contents but its text is not included in the pages provided.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Nov 2026board outcome
Acquisition, Dividend / buy-back, Management change, Results
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026.
AI summary

Dr. Lal PathLabs Limited filed the outcome of its board meeting held on November 04, 2026, approving unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026.

The board declared a 2nd interim dividend of INR 5 per equity share (50% on face value of INR 10), with record date November 11, 2026, payable within 30 days of declaration.

The board appointed Ms. Vasuta Agarwal as an Additional Director (Non-Executive Independent) for three years from November 04, 2026, subject to shareholder approval by postal ballot.

The board approved further investment of up to INR 49.5 crore in Dr. Lal PathLabs FZCO (wholly owned subsidiary) in one or more tranches.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Nov 2026dividend
Capex, Dividend / buy-back, Management change, Results
Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on November 04, 2026, declared 2nd Interim Dividend of Rs. 5 per equity share.
AI summary

Board of Dr. Lal PathLabs Limited, meeting held November 04, 2026, approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with a limited review report from Deloitte Haskins & Sells LLP.

Declared 2nd interim dividend of INR 5 per equity share (50% on face value of INR 10) for FY 2026-27, record date November 11, 2026; to be paid within 30 days of declaration.

Appointed Ms. Vasuta Agarwal as Additional Director (Non-Executive Independent) for three years from November 04, 2026, subject to members' approval by postal ballot.

Approved further investment of up to INR 49.5 crore in Dr. Lal PathLabs FZCO (wholly owned subsidiary) in one or more tranches.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Nov 2026board outcome
Acquisition, Dividend / buy-back, Management change, Results
Dr. Lal Path Labs Ltd. has submitted to the Exchange, the financial results for the period ended September 30, 2026.
AI summary

Board of Dr. Lal PathLabs Limited approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with a limited review report from Deloitte Haskins & Sells LLP.

Board declared a 2nd interim dividend of INR 5 per equity share (50% on face value of INR 10), record date November 11, 2026, to be paid within 30 days of declaration.

Board appointed Ms. Vasuta Agarwal as Additional Director (Non-Executive Independent) for three years from November 4, 2026, subject to shareholder approval by postal ballot.

Board approved further investment of up to INR 49.5 crore in Dr. Lal PathLabs FZCO, a wholly owned subsidiary, in one or more tranches.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Sep 2026board outcome
Acquisition
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on September 24, 2026.
AI summary

Dr. Lal PathLabs' board, meeting held September 24, 2026, approved the acquisition of a 70% stake in SN Genelab Private Limited (SN Gene) from its existing shareholders; SN Gene will become a subsidiary.

Cash consideration of up to INR 168 Crores plus performance-linked earn-out capped at INR 31.5 Crores for the 70% stake; completion expected by November 30, 2026.

SN Gene, incorporated December 16, 2013 in Gujarat, provides diagnostics-genomics services; turnover was INR 57.96 Crores (FY 2026), INR 53.36 Crores (FY 2025) and INR 43.27 Crores (FY 2024).

The company stated the acquisition is to strengthen its genomics expertise and broaden its advanced diagnostic services portfolio; no governmental or regulatory approvals are required and it is not a related party transaction.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jul 2026transcript
Acquisition, Dividend / buy-back, Guidance, Results
Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript
AI summary

Dr. Lal PathLabs filed the transcript of its Q1 FY27 earnings conference call held on July 24, 2026.

Management reported Q1 FY27 revenue of Rs. 798 crore, up 19.1% year-on-year, with EBITDA of Rs. 247 crore (31.0% margin) and PAT of Rs. 170 crore (21.4% margin).

The board declared an interim dividend of 50% (Rs 5 per share) and approved an acquisition of 80% in Sunshine Healthcare Limited, Ghana, for up to GHS 45.6 million, and a 30% stake in Neuome Technologies Private Limited for up to Rs 3.5 crore.

Management said Q1 results were slightly ahead of expectations and that revenue growth may be towards mid-teens rather than early teens for the year, with a forecast update after the first half.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Jul 2026presentation
Results
Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation
AI summary

Dr. Lal PathLabs filed its earnings presentation on unaudited standalone and consolidated results for the quarter ended June 30, 2026 (Q1 FY27), approved by the Board on July 24, 2026.

Q1 FY27 revenue was Rs. 798 crore, up 19.1% from Rs. 670 crore in Q1 FY26; EBITDA was Rs. 247 crore (margin 31.0%) versus Rs. 192 crore; PAT was Rs. 170 crore, up 27.2% from Rs. 134 crore.

Q1 FY27 sample volumes grew 10.7% year on year to 8.2 million and patient volumes grew 8.2% to 25.9 million (as printed in the presentation).

Management said Q1 FY27 was the highest quarterly revenue growth in the last four years, and that volume-led revenue growth drove the quarter's performance.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Jul 2026board outcome
Acquisition, Dividend / buy-back, Results
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on July 24, 2026.
AI summary

Board of Dr. Lal PathLabs Limited, meeting held July 24, 2026, approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a Limited Review Report from Deloitte Haskins & Sells LLP.

Board approved an interim dividend of INR 5 per equity share (50% on face value of INR 10) for FY 2026-27, with record date July 30, 2026; payment to be made within 30 days of declaration.

Board approved grant of stock options under the Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 to eligible employees.

Board took note of acquisition of stake in Sunshine Healthcare Limited, Ghana, approved by Dr Lal PathLabs FZCO, Dubai, a wholly owned subsidiary.

Board took note of acquisition of stake in Neuome Technologies Private Limited, approved by Dr. Lal Ventures Private Limited, a wholly owned subsidiary.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Jul 2026dividend
Acquisition, Dividend / buy-back, Results
Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on July 24, 2026, declared Interim Dividend of Rs. 5 per equity share.
AI summary

Board of Dr. Lal PathLabs met on July 24, 2026 and approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a limited review report from Deloitte Haskins & Sells LLP.

Board approved an interim dividend of INR 5 per equity share (50% on face value of INR 10) for FY 2026-27, with record date July 30, 2026; payment to be made within 30 days of declaration.

Board approved grant of stock options under Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 to eligible employees.

Board noted approval by Dr Lal PathLabs FZCO (Dubai, wholly owned subsidiary) of acquisition of stake in Sunshine Healthcare Limited, Ghana, and by Dr. Lal Ventures Private Limited (wholly owned subsidiary) of acquisition of stake in Neuome Technologies Private Limited.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Jul 2026board outcome
Acquisition, Dividend / buy-back, Results
Dr. Lal Path Labs Ltd. has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
AI summary

Board of Dr. Lal PathLabs approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a limited review report from Deloitte Haskins & Sells LLP attached.

Board approved an interim dividend of INR 5 per equity share (50% on face value of INR 10) for FY 2026-27, with record date July 30, 2026; payment to be made within 30 days of declaration.

Board approved grant of stock options under Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 to eligible employees.

Board took note of acquisition of stake in Sunshine Healthcare Limited, Ghana, approved by Dr Lal PathLabs FZCO, Dubai (wholly owned subsidiary).

Board took note of acquisition of stake in Neuome Technologies Private Limited, approved by Dr. Lal Ventures Private Limited (wholly owned subsidiary).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 May 2026transcript
Acquisition, Dividend / buy-back, Guidance, Results
Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript
AI summary

Dr. Lal PathLabs filed the transcript of its Q4 & FY26 earnings conference call held April 30, 2026.

Q4 FY26 revenue was Rs. 703 crore (up 16.6%); FY26 revenue was Rs. 2,763 crore (up 12.2%). Q4 FY26 EBITDA was Rs. 187 crore (26.6% margin); FY26 PAT was Rs. 510 crore.

The Board approved a final dividend of Rs. 4 per share, taking the FY26 total to Rs. 20.5 per share (after the 1:1 bonus issue in Q3 FY26).

CEO Shankha Banerjee said the company is targeting early to mid-teens revenue growth in FY27; CFO Ved Goel guided to an EBITDA margin of 27% to 28% for next year.

Management discussed the acquisition of an asset in Mumbai (Shahbaz Labs), which Ved Goel described as a small pathology business with about Rs. 6 crore of turnover.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Apr 2026presentation
Results
Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation
AI summary

Dr. Lal PathLabs filed its Q4 & FY26 earnings presentation on audited standalone and consolidated results for the quarter and year ended March 31, 2026, approved by the Board on April 30, 2026.

Q4 FY26 revenue was Rs. 703 crore, up 16.6% from Rs. 603 crore in Q4 FY25; Q4 reported PAT was Rs. 132 crore versus Rs. 156 crore a year earlier, down 15.1%.

FY26 revenue was Rs. 2,763 crore, up 12.2% from Rs. 2,461 crore; FY26 reported PAT was Rs. 510 crore versus Rs. 492 crore, up 3.6%.

Normalized FY26 EBITDA was Rs. 783 crore (up 12.5%) and normalized PAT was Rs. 532 crore (up 17.9%), excluding a Rs. 30 crore one-time labour code impact and other items.

The presentation shows a dividend for FY25-26 of 312% and a credit rating of AA+ Stable from Care Ratings, as stated in the company overview.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Apr 2026board outcome
Acquisition, Capex, Dividend / buy-back, Legal, Management change, Results
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on April 30, 2026.
AI summary

Board of Dr. Lal PathLabs approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.

Board recommended a final dividend of INR 4 per equity share (40% on face value of INR 10), subject to AGM approval, with record date June 26, 2026.

Board approved acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited from its existing shareholders, making it a wholly owned subsidiary.

Board approved incorporation of a wholly owned subsidiary in Dubai, UAE, named Dr. Lal PathLabs FZCO, subject to approvals.

Board approved re-appointment of Arvind Lal as Executive Chairman and Whole-Time Director for five years from April 1, 2027, and of Rajit Mehta as Non-Executive Independent Director for five years from July 27, 2026, both subject to AGM approval.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Apr 2026dividend
Acquisition, Capex, Dividend / buy-back, Legal, Management change, Results
Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on April 30, 2026, recommended Final Dividend of Rs. 4 per equity share.
AI summary

Board of Dr. Lal PathLabs approved audited standalone and consolidated results for the quarter and year ended March 31, 2026, and recommended a final dividend of INR 4 per equity share (40% on face value of INR 10), with record date June 26, 2026, subject to AGM approval.

The Board approved acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited from its existing shareholders, which will become a wholly owned subsidiary.

The Board approved incorporation of a wholly owned subsidiary in Dubai, UAE, named Dr. Lal PathLabs FZCO, subject to regulatory approvals.

The Board approved re-appointment of (Hony) Brig. Dr. Arvind Lal as Executive Chairman and Whole-Time Director for five years from April 1, 2027, and of Mr. Rajit Mehta as Non-Executive Independent Director for five years from July 27, 2026, both subject to AGM approval.

The Board allotted 82,750 equity shares under Employee Stock Option Plan 2022 and convened the 32nd AGM on July 25, 2026 via VC/OAVM.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Apr 2026board outcome
Acquisition, Capex, Dividend / buy-back, Management change, Results
Dr. Lal Path Labs Ltd. has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Board meeting held April 30, 2026 approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with auditors' reports attached.

Board recommended final dividend of INR 4 per equity share (40% on face value of INR 10) for FY2025-26, subject to AGM approval; record date June 26, 2026.

Board approved acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited from its existing shareholders, which will become a wholly owned subsidiary.

Board approved incorporation of a wholly owned subsidiary in Dubai, UAE, named Dr. Lal PathLabs FZCO, subject to approvals.

Board approved re-appointment of Dr. Arvind Lal as Executive Chairman and Whole-Time Director for five years from April 1, 2027, and of Mr. Rajit Mehta as Non-Executive Independent Director for five years from July 27, 2026, both subject to AGM approval.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
25 Mar 2026credit rating
Rating
Dr. Lal Path Labs Ltd. has informed the Exchange about Credit Rating- Revision (Upgraded from CARE AA; Stable to CARE AA+; Stable)
AI summary

Dr. Lal PathLabs Limited intimated under Regulation 30 that CARE Ratings Limited, by letter dated March 25, 2026, upgraded the company's issuer rating.

The issuer rating was upgraded to CARE AA+; Stable from CARE AA; Stable.

The rating committee reviewed operational and financial performance for FY25 (audited) and 9MFY26 (un-audited).

CARE states the rating is an opinion on general creditworthiness and not specific to any debt instrument.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Feb 2026transcript
Dividend / buy-back, Guidance, Results
Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript
AI summary

Dr. Lal PathLabs filed the transcript of its Q3 & 9M FY26 earnings conference call held on January 30, 2026.

Q3 FY26 revenue was Rs. 660 crore, up 10.6% YoY from Rs. 597 crore; 9M FY26 revenue was Rs. 2,060 crore, up 10.8%.

Q3 FY26 EBITDA before exceptional item was Rs. 179 crore (27.2% margin) after a one-time Rs. 30 crore labour code cost reported as exceptional; Q3 PAT was Rs. 91 crore versus Rs. 98 crore last year.

Management (CEO Shankha Banerjee) said it expects 11% to 12% organic revenue growth for the year and that patient volume growth was 2.7% in Q3 due to a decline in the seasonal fever portfolio.

Management (Executive Chairman Dr. Arvind Lal) said the company approved an interim dividend of Rs. 3.5 per share (35%) on enhanced equity capital after a 1:1 bonus issue.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2026presentation
Results
Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation
AI summary

Dr. Lal PathLabs filed its Q3 & 9M FY26 earnings presentation (unaudited consolidated and standalone results for the quarter and nine months ended December 31, 2025), approved by the Board on January 30, 2026.

Q3 FY26 revenue was Rs. 660 crore, up 10.6% from Rs. 597 crore in Q3 FY25; EBITDA before exceptional items was Rs. 179 crore (up 16.3%); PAT was Rs. 91 crore, down 6.8% from Rs. 98 crore, after exceptional items of Rs. 30.1 crore.

The presentation shows an impact of Labour Codes of Rs. 30 crore on Q3 FY26 EBITDA, reducing reported EBITDA to Rs. 149 crore.

9M FY26 revenue was Rs. 2,060 crore, up 10.8%; EBITDA before exceptional items was Rs. 596 crore (up 13.1%); PAT was Rs. 378 crore, up 12.2%.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2026board outcome
Dividend / buy-back, Results
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on January 30, 2026.
AI summary

Board outcome filed for Dr. Lal PathLabs: the board on January 30, 2026 approved unaudited consolidated and standalone results for the quarter and nine months ended December 31, 2025, with a limited review report from Deloitte Haskins & Sells.

Consolidated revenue from operations for Q3 FY26 was INR 6,598 million, against INR 7,306 million in the preceding quarter and INR 5,967 million a year earlier; consolidated profit for the period was INR 914 million for the quarter and INR 3,776 million for nine months.

Board declared a 3rd interim dividend of INR 3.5 per equity share (35% on face value of INR 10) for FY 2025-26, with a record date of February 5, 2026.

Board allotted 4,000 equity shares under the Employee Stock Option Plan 2010; paid-up equity share capital rose to INR 1,67,55,50,200.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2026dividend
Dividend / buy-back, Results
Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on January 30, 2026, declared Interim Dividend of Rs. 3.5 per equity share.
AI summary

Board meeting outcome dated January 30, 2026: unaudited consolidated and standalone results for the quarter and nine months ended December 31, 2025 approved, with limited review report from Deloitte Haskins & Sells LLP.

Consolidated Q3 FY26 revenue from operations INR 6,598 million; profit for the period INR 914 million; basic EPS INR 5.42 (not annualised).

Nine-month consolidated revenue from operations INR 20,602 million; profit for the period INR 3,776 million; basic EPS INR 22.38.

Board declared 3rd interim dividend of INR 3.5 per equity share (35% on face value of INR 10) for FY 2025-26, with record date February 5, 2026.

Allotment of 4,000 equity shares under ESOP 2010; paid-up equity share capital now INR 1,67,55,50,200.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2026board outcome
Dividend / buy-back, Results
Dr. Lal Path Labs Ltd. has submitted to the Exchange, the financial results for the period ended December 31, 2025.
AI summary

Board outcome filing: the Board of Dr. Lal PathLabs Limited approved unaudited consolidated and standalone financial results for the quarter and nine months ended December 31, 2025, with a Limited Review Report from Deloitte Haskins & Sells LLP.

Consolidated revenue from operations was INR 6,598 million for the quarter and INR 20,602 million for nine months; consolidated profit for the period was INR 914 million for the quarter and INR 3,776 million for nine months.

The Board declared a 3rd interim dividend of INR 3.5 per equity share (35% on face value of INR 10) for FY 2025-26, with record date February 5, 2026; it will be credited within 30 days of declaration.

The Company allotted 4,000 equity shares under Employee Stock Option Plan 2010, taking paid-up equity share capital to INR 1,67,55,50,200 (16,75,55,020 equity shares of INR 10 each).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2025transcript
Dividend / buy-back, Guidance, Results
Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript
AI summary

Dr. Lal PathLabs filed the transcript of its Q2 and H1 FY26 earnings conference call held on October 31, 2025.

Management said Q2 FY26 revenue was Rs. 731 crore (up 10.7% YoY) and H1 FY26 revenue was Rs. 1,400 crore (up 11%); Q2 PAT was Rs. 152 crore (up 16.4%) and H1 PAT was Rs. 286 crore (up 20%).

Management said Q2 EBITDA was Rs. 224 crore (30.7% margin) and net cash as of September 30, 2025 was Rs. 1,367 crore.

The Board approved an interim dividend of 70%, i.e. Rs. 7 per share, and a bonus issue in the ratio of 1:1.

Management reiterated FY26 revenue growth guidance of 11% to 12% and said FY26 margins are likely to be in the range of 27% to 28%.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Oct 2025presentation
Dividend / buy-back, Results
Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation
AI summary

Dr. Lal PathLabs filed its Q2 & H1 FY26 earnings presentation for the quarter and half year ended September 30, 2025, following Board approval of unaudited standalone and consolidated results on October 31, 2025.

Q2 FY26 revenue was Rs. 731 crore (up 10.7% from Rs. 660 crore in Q2 FY25); EBITDA was Rs. 224 crore (up 10.8%); PAT was Rs. 152 crore (up 16.4%).

H1 FY26 revenue was Rs. 1,400 crore (up 11.0% Y-o-Y); H1 FY26 EBITDA rose 11.8% Y-o-Y, and H1 PAT was Rs. 286 crore.

Management said H1 growth was mainly sample volume driven (+10.4% Y-o-Y), led by network expansion in core metro markets and deeper penetration in Tier 3 and Tier 4 cities; SwasthFit contributed 27% of H1 FY26 revenue.

The Board approved a dividend of 70% (Rs. 7 per share) and a bonus issue in the ratio of 1:1, with the record date as stated in the filing.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Oct 2025board outcome
Capex, Dividend / buy-back, Results
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on October 31, 2025.
AI summary

Board of Dr. Lal PathLabs approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, with a Limited Review Report from the statutory auditors (Deloitte Haskins & Sells LLP).

Board declared a 2nd Interim Dividend of INR 7 per equity share (70% of face value of INR 10) for FY 2025-26, with record date November 7, 2025.

Board approved issuance of bonus equity shares in the ratio 1:1, subject to member and regulatory approvals; record date to be announced later.

Board approved increase in authorised share capital from INR 1,07,96,00,000 to INR 2,00,00,00,000 via alteration of Clause V of the Memorandum of Association, subject to member approval.

Board approved introduction of "Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025" with shares reserved by reducing the ESOP 2022 pool, subject to member approval.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Oct 2025bonus split
Capex, Dividend / buy-back, Results
Dr. Lal Path Labs Ltd. has informed the Exchange that the Board of Directors at its meeting held on October 31, 2025, have considered and approved bonus at the ratio of 1 : 1, i.e 1 Equity Shares for every 1 Equity Shares held.
AI summary

Board of Dr. Lal PathLabs approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, with a limited review report from Deloitte Haskins & Sells LLP.

Board declared a 2nd interim dividend of INR 7 per equity share (70% of face value of INR 10) for FY 2025-26, with record date November 7, 2025.

Board approved a bonus issue of 1:1 (one bonus equity share for every one share held) of face value INR 10 each, subject to member and regulatory approvals; record date to be announced later.

Board approved increasing authorised share capital from INR 1,07,96,00,000 to INR 2,00,00,00,000, subject to member approval.

Board approved the "Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025" (RSU 2025), with shares reserved by reducing the ESOP 2022 pool, subject to member approval.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Oct 2025dividend
Capex, Dividend / buy-back, Legal, Results
Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on October 31, 2025, declared Interim Dividend of Rs. 7 per equity share.
AI summary

Board of Dr. Lal PathLabs approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, with a limited review report from Deloitte Haskins & Sells LLP.

Board declared a 2nd interim dividend of INR 7 per equity share (70% of face value of INR 10) for FY 2025-26, with record date November 7, 2025; payment within 30 days of declaration.

Board approved a bonus issue of 1:1 (one new equity share for every one held), subject to member and regulatory approvals; record date to be announced later.

Board approved raising authorised share capital from INR 1,07,96,00,000 to INR 2,00,00,00,000, subject to member approval.

Board approved the Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025, with reserve created by reducing the ESOP 2022 pool, subject to member approval.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Oct 2025board outcome
Capex, Dividend / buy-back, Results
Dr. Lal Path Labs Ltd. has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Board of Dr. Lal PathLabs approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, with a limited review report from the statutory auditor.

The Board declared a 2nd interim dividend of INR 7 per equity share (70% of face value of INR 10) for FY 2025-26, with record date November 7, 2025.

The Board approved a bonus issue of 1:1 (one bonus equity share of INR 10 for every one held), subject to member and regulatory approvals; the record date will be announced later.

The Board approved increasing authorised share capital from INR 1,07,96,00,000 to INR 2,00,00,00,000, subject to member approval.

The Board approved the introduction of the "Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025", subject to member approval.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Aug 2025transcript
Capex, Dividend / buy-back, Guidance, Results
Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript
AI summary

Dr. Lal PathLabs filed the transcript of its Q1 FY26 and FY26 earnings conference call held on July 31, 2025.

Management reported Q1 FY26 revenue of Rs. 670 crore, up 11.3% from Rs. 602 crore, and PAT of Rs. 134 crore, up 24.3%, with EBITDA margin of 28.7%.

Management said the Board approved an interim dividend of 60% (Rs. 6 per share).

Management said the company expects to add a similar number of labs (18 in FY25) in the current year and that the second half will carry most of its investments, so the first-half margin is not representative of the full year.

Management said the annual margin could be slightly better than projected at the start of the year.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Jul 2025presentation
Results
Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation
AI summary

Dr. Lal PathLabs filed its Q1 FY26 earnings presentation on unaudited standalone and consolidated results for the quarter ended June 30, 2025, approved by the Board on July 31, 2025.

Q1 FY26 revenue was Rs. 670 crore, up 11.3% year-on-year from Rs. 602 crore; EBITDA was Rs. 192 crore (up 13.1%) and PAT was Rs. 134 crore (up 24.3%) versus Rs. 108 crore.

Management said revenue growth was mainly sample-volume driven (up 10.7% year-on-year), led by calibrated network expansion in core metro markets and deeper penetration in Tier 3 and Tier 4 cities/towns.

Management said SwasthFit contributed 27% of Q1 FY26 revenue, and EBITDA growth was driven by volume growth, network expansion, favourable mix and hub-and-spoke efficiencies.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Jul 2025board outcome
Dividend / buy-back, Legal, Results
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on July 31, 2025.
AI summary

Board of Dr. Lal PathLabs Limited, meeting held on July 31, 2025, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a Limited Review Report from Deloitte Haskins & Sells LLP attached.

The Board declared an interim dividend of INR 6 per equity share (60% on face value of INR 10) for financial year 2025-26.

The record date for the interim dividend is August 06, 2025, and it will be dispatched or credited within 30 days of declaration.

The Board also approved an amendment to the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.

The board meeting commenced at 11:00 A.M. and concluded at 1:15 P.M. (IST).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Jul 2025dividend
Dividend / buy-back, Legal, Results
Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on July 31, 2025, declared Interim Dividend of Rs. 6 per equity share.
AI summary

Board of Dr. Lal PathLabs Limited met on July 31, 2025 and approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a Limited Review Report from Deloitte Haskins & Sells LLP.

The Board declared an interim dividend of INR 6 per equity share (60% on face value of INR 10) for financial year 2025-26.

The record date for the interim dividend is August 06, 2025, and it will be dispatched or credited within 30 days of declaration.

The Board also approved an amendment to the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.

The page text is partly garbled, so the quarterly figures in the results tables could not be reliably read and are not stated here.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Jul 2025board outcome
Dividend / buy-back, Legal, Results
Dr. Lal Path Labs Ltd. has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AI summary

Board meeting held on July 31, 2025 approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a limited review report from Deloitte Haskins & Sells LLP.

The Board declared an interim dividend of INR 6 per equity share (60% on face value of INR 10) for FY 2025-26, with record date August 06, 2025.

The interim dividend will be dispatched or credited within 30 days of declaration.

The Board also approved an amendment to the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 May 2025transcript
Acquisition, Capex, Dividend / buy-back, Guidance, Results
Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript
AI summary

Dr. Lal PathLabs filed the transcript of its Q4 & FY25 earnings conference call held on April 25, 2025.

Ved Prakash Goel (Group CFO) said Q4 FY25 revenue was Rs. 603 crore (up 10.5% from Rs. 545 crore) and FY25 revenue was Rs. 2,461 crore (up 10.5% from Rs. 2,227 crore).

Q4 FY25 PAT was Rs. 156 crore (up 81.4%), including a one-time deferred tax benefit of Rs. 40.8 crore from the voluntary liquidation of Suburban Diagnostics; normalized EPS for Q4 FY25 was Rs. 13.6 and for FY25 was Rs. 53.5.

The Board approved a final dividend of 60% (Rs. 6 per share), taking the total FY25 dividend to 240% (Rs. 24 per share).

Shankha Banerjee (CEO) said the company added 18 labs during the year and expects to keep adding labs at a similar pace, and that the Suburban business has been transferred to Dr. Lal PathLabs on a going-concern basis.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
25 Apr 2025presentation
Dividend / buy-back, Results
Dr. Lal Path Labs Ltd. has informed the Exchange about Presentation
AI summary

Dr. Lal PathLabs filed its Q4 & FY25 earnings presentation on audited standalone and consolidated results for the quarter and year ended March 31, 2025, approved by the Board on April 25, 2025.

Q4 FY25 revenue was Rs. 603 crore (up 10.5% from Rs. 545 crore); EBITDA was Rs. 169 crore (margin 28.1%); reported PAT was Rs. 156 crore versus Rs. 86 crore in Q4 FY24, including a one-time deferred tax impact of Rs. 41 crore from SDIPL voluntary liquidation.

FY25 revenue was Rs. 2,461 crore (up 10.5%); EBITDA was Rs. 696 crore (up 14.2%); reported PAT was Rs. 492 crore (up 35.9%); PAT excluding one-time adjustment was Rs. 451 crore (up 24.6%).

The presentation lists a dividend for FY24-25 and reports 6,607 patient service centres and 40 NABL accredited labs as of March 31, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
25 Apr 2025board outcome
Dividend / buy-back, Legal, Management change, Results
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on April 25, 2025.
AI summary

Dr. Lal PathLabs Limited filed the outcome of its board meeting held on April 25, 2025, approving audited standalone and consolidated financial results for the quarter and year ended March 31, 2025.

The board recommended a final dividend of INR 6 per equity share (60% on face value of INR 10), subject to member approval at the AGM, with a record date of June 06, 2025.

The board approved re-appointment of Rohit Bhasin as Non-Executive Independent Director for five years from November 08, 2025, and Arun Duggal for three years from February 02, 2026, both subject to member approval.

The board approved re-appointment of Ernst & Young LLP as internal auditors for FY 2025-26, re-appointment of A.G. Agarwal & Associates as cost auditors for FY 2025-26, and appointment of Chandrasekaran Associates as secretarial auditors for five years from FY 2025-26.

The 31st AGM is convened for Saturday, June 28, 2025, through video conferencing or other audio-visual means.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
25 Apr 2025dividend
Dividend / buy-back, Legal, Management change, Results
Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on April 25, 2025, recommended Final Dividend of Rs. 6 per equity share.
AI summary

Dr. Lal PathLabs' board, meeting held April 25, 2025, approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with auditor reports attached.

Board recommended a final dividend of INR 6 per equity share (60% on face value of INR 10) for FY2024-25, subject to member approval at the AGM; record date June 06, 2025.

Board approved re-appointment of Rohit Bhasin as Non-Executive Independent Director for five years from November 08, 2025, and Arun Duggal for three years from February 02, 2026, both subject to member approval.

Board approved re-appointment of Ernst & Young LLP as internal auditors and A.G. Agarwal & Associates as cost auditors for FY2025-26, and appointment of Chandrasekaran Associates as secretarial auditors for FY2025-26 to FY2029-30.

Board convened the 31st AGM on Saturday, June 28, 2025, through VC/OAVM.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
25 Apr 2025board outcome
Dividend / buy-back, Management change, Results
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on April 25, 2025.
AI summary

Board of Dr. Lal PathLabs Limited, meeting held April 25, 2025, approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with auditor reports attached (Deloitte Haskins & Sells LLP, consolidated audit report).

Recommended final dividend of INR 6 per equity share (60% on face value of INR 10), subject to member approval at the AGM; record date June 06, 2025.

Re-appointed Mr. Rohit Bhasin as Non-Executive Independent Director for five years from November 08, 2025, and Mr. Arun Duggal for three years from February 02, 2026, both subject to member approval at the AGM.

Re-appointed EY LLP as Internal Auditors and A.G. Agarwal & Associates as Cost Auditors for FY 2025-26; appointed Chandrasekaran Associates as Secretarial Auditors for FY 2025-26 to FY 2029-30, subject to member approval.

Convened the 31st AGM on Saturday, June 28, 2025, through VC/OAVM.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 Apr 2025credit rating
Rating
Dr. Lal Path Labs Ltd. has informed the Exchange about Credit Rating
AI summary

Dr. Lal PathLabs Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, dated April 22, 2025.

CARE Ratings Limited assigned an Issuer Rating of "CARE AA; Stable" to the company, with the rating action shown as "Assigned".

The rating was assigned by CARE's Rating Committee and is normally valid for one year from the initial communication date of March 28, 2025.

CARE states the rating is an opinion on the general creditworthiness of the company, not specific to any debt instrument, and the rationale will be communicated separately.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Mar 2025credit rating
Rating
Dr. Lal Path Labs Ltd. has informed the Exchange about withdrawal of Credit Rating by CARE Ratings
AI summary

Dr. Lal PathLabs Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, dated March 14, 2025.

CARE Ratings Limited, by letter dated March 13, 2025, withdrew the credit rating on the Company's long term bank facilities of INR 104.17 crore, with immediate effect.

The Company requested the withdrawal because the rated bank facility (HDFC Bank term loan) was fully repaid.

CARE stated it will announce the withdrawal through a press release and asked that the ratings not be used for any purpose.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in